Clinical Trial Update: Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MT027 in patients with recurrent or progressive glioblastoma. The trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• MT027

Snippet

Sponsor: Suzhou Maximum Bio-tech Co., Ltd. | Conditions: High-grade Glioma | Phase 1 | Status: NOT_YET_RECRUITING